Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

DISEASE CHARACTERISTICS: Histologically confirmed ovarian epithelial, fallopian tube, or peritoneal cancer Stage II-IV Initially treated with surgery and at least 1 platinum-based chemotherapy regimen Must have relapsed after initial treatment and completed chemotherapy for recurrent disease Asymptomatic residual measurable disease on CT scan and/or an elevated CA 125 allowed Complete clinical remission allowed, defined by the following criteria: CA 125 no greater than 35 IU/mL No objective evidence of disease by CT scan Normal physical examination PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 70-100% Life expectancy At least 3 months Hematopoietic WBC at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic Bilirubin no greater than 2 times normal ALT no greater than 2 times normal Alkaline phosphatase no greater than 2 times normal Renal Creatinine no greater than 1.5 times normal Other Not pregnant or nursing No potential for child bearing Human antimurine antibody negative HIV negative No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix No active infection No known autoimmune disease (e.g., rheumatoid arthritis or ulcerative colitis) No known immune deficiency (e.g., hypogammaglobulinemia) No known allergy to murine proteins PRIOR CONCURRENT THERAPY: Biologic therapy At least 6 weeks since prior interferon At least 6 weeks since prior immunotherapy or biological response modifiers No prior anticancer vaccine Chemotherapy See Disease Characteristics At least 3 weeks since prior cytotoxic or investigational chemotherapy Endocrine therapy No concurrent steroids Radiotherapy At least 4 weeks since prior radiotherapy Surgery See Disease Characteristics Other At least 1 week since prior antibiotics No concurrent cyclosporine No other concurrent immunosuppressive therapy